News & Events CTI CEO to Present at 8th Congress on Pediatric Transplantation

CTI CEO to Present at 8th Congress on Pediatric Transplantation

March 24, 2015

CTI Clinical Trial and Consulting Services CEO to Present at 8th Congress on Pediatric Transplantation

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ March 24, 2015]  

CTI Clinical Trial and Consulting Services (CTI) will present at the 8th Congress on Pediatric Transplantation, sponsored by the International Pediatric Transplant Association (IPTA). The meeting takes place March 28-31, 2015 in San Francisco, California. CTI’s Chief Executive Officer, Timothy J. Schroeder, will speak as part of the 'Plenary Symposium III: The Future of Immunosuppressive Therapy in Children after Solid Organ Transplantation', and will present “Designing and Implementing Clinical Trials: Can We Do It In Pediatric Solid Organ Transplant?”. 

“I am very excited to be a part of this congress, as advances in pediatric transplant research are greatly needed,” according to Schroeder. “Approximately 20% of the research studies that CTI manages on behalf of pharmaceutical and biotechnology companies involve neonates and children, which often encompass unique challenges in conducting successful clinical programs.”

Schroeder, CTI’s founder, has over 30 years of clinical, academic, and industry experience in leading multi-national Phase I through Phase IV drug development programs. He leads CTI’s growth strategy which now encompasses offices in more than 20 countries across four continents. He also consults with pharmaceutical and biotechnology companies on strategic decisions surrounding clinical and commercial drug development issues, and has served as a reviewer to numerous FDA Advisory Panels, including CDER and CBER. Prior to founding CTI, he held numerous faculty positions with the University of Cincinnati College of Medicine and was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, where he oversaw the development of biological agents, generic drugs, diagnostics, preservation solutions, and therapeutic agents for use in the transplant field.


About International Pediatric Transplant Association

The International Pediatric Transplant Association (IPTA) is a non-profit, professional organization of individuals in the field of pediatric transplantation. The purpose of the association is to advance the science and practice of pediatric transplantation worldwide and to advocate for the health of all children who require such treatment. IPTA is the only worldwide organization solely focused on pediatric transplantation. With over 650 members from more than 54 countries worldwide, our members represent all areas of pediatric transplantation.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology,  cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe, South America, and Pac-Asia.

Original Press Release

Subscribe to our mailing list

* indicates required